Wuxi Biologics Placement - Smaller Deal than Previous as Last Didn’t Do Well, Overhang Remain
Wuxi Biologics Holdings is looking to raise up to US$288m by selling about 2% of Wuxi Biologics (2269 HK). This will be the 17th placement in the...
710 Views
Keymed Bioscience Placement - Track Record Isn’t Great but Recent Performance Has Been Better
Keymed Biosciences (2162 HK), along with its controlling shareholder, is looking to raise around US$112m to fund its R&D requirements.
418 Views
Jiangsu Hengrui Pharma A/H Trading - Strong Demand for Quality Asset, but Is Pricey
Jiangsu Hengrui Pharmaceuticals (1276 HK) (JHP, 600276 CH ), a China-based pharmaceutical company, raised around US$1.5bn in its H-share listing....
416 Views
HK Connect Flows Weekly (May 16th): Biggest Weekly Outflows in a Year
We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for CCB, BOC, CMB, China Shenhua Energy, CNOOC, Tencent,...
387 Views
Jiangsu Hengrui Pharma A/H Listing - Low-End Is Probably Close to Fair Value
Jiangsu Hengrui Medicine (600276 CH), a China-based pharmaceutical company, aims to raise around US$1.3bn in its H-share listing. In this note, we...
634 Views